Johnson & Johnson vs Pfizer: a complete comparison of OVR ratings, fundamentals, volatility, and characteristics.
JNJ is rated 85 OVR (A-Tier (Strong)) — Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 co
PFE is rated 64 OVR (C-Tier (Speculative)) — Pfizer's post-COVID revenue collapse removed billions from annual revenue. The pipeline must replace
| METRIC | JNJ (Johnson & Johnson) | PFE (Pfizer) |
|---|---|---|
| OVR Rating | 85 | 64 |
| Tier | A-Tier (Strong) | C-Tier (Speculative) |
| Momentum | 45/100 | 28/100 |
| Stability | 92/100 | 70/100 |
| Value Score | 75/100 | 78/100 |
| Revenue Growth | +5% | -41% |
| P/E Ratio | 14x | 14x |
| Beta (Volatility) | 0.45 | 0.55 |
| Market Cap | $380B | $150B |
| Dividend Yield | 3.3% | 6.1% |
| S&P 500 | Yes | Yes |
| NFL Comparison | Frank Gore | Cam Newton |
| Sector | Healthcare | Healthcare |
Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 consecutive years — one of the longest streaks of any public company.
Pfizer's post-COVID revenue collapse removed billions from annual revenue. The pipeline must replace this shortfall. Trading at 14x P/E — cheap only if the pipeline delivers.
Explore both on MarketMVP
Free platform · Sports-style player ratings for every stock
OPEN MARKETMVP FREE →Educational purposes only. MarketMVP OVR scores, tiers, and athlete comparisons are proprietary educational tools — not financial advice, investment ratings, or recommendations to buy or sell any security. Always conduct your own research. Full disclaimer